<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884829</url>
  </required_header>
  <id_info>
    <org_study_id>CYC140-01</org_study_id>
    <nct_id>NCT03884829</nct_id>
  </id_info>
  <brief_title>A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS</brief_title>
  <official_title>A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients With Advanced Leukemias or Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclacel Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cyclacel Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with
      Advanced Leukemias or Myelodysplastic Syndromes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a First in Human, open-label, single arm, dose escalation study in patients with
      advanced leukemias or myelodysplastic syndromes. Patients will receive CYC140 as a 1 hr
      infusion once a week for 2 weeks followed by 1 week of rest on an outpatient basis. One
      treatment cycle is 3 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 26, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One to three patients will be entered at a given dose level of CYC140. During the first cycle, all patients will be evaluated for DLTs. If DLT occurs, additional patients (up to 3) will be dosed at that dose. If no additional DLTs observed, dose escalation will continue per protocol. If a DLT does occur, dose escalation will be stopped. At least 6 patients will be treated at the RD to confirm its tolerability.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients who experience dose -limiting toxicity (DLT)</measure>
    <time_frame>At end of cycle 1 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measurement - area under the curve (AUC)</measure>
    <time_frame>At the end of cycle 1 (each cycle is 21 days)</time_frame>
    <description>plasma drug exposure area under the curve (AUC)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>First dose of CYC140 to 4 weeks after the last dose of CYC140</time_frame>
    <description>complete remission, partial remission</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>AML, Adult</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>ALL, Adult</condition>
  <condition>CML, Refractory</condition>
  <condition>CLL, Refractory</condition>
  <arm_group>
    <arm_group_label>CYC140 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYC140 will be administered as a single agent on Day 1 and Day 8 of each 3 week cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYC140</intervention_name>
    <description>CYC140 single agent</description>
    <arm_group_label>CYC140 single agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of relapsed or refractory advanced leukemias or MDS

          -  ECOG 0-2

          -  Adequate renal function

          -  Adequate liver function

          -  ≥ 2 weeks from prior chemotherapy, radiation therapy or major surgery

          -  ≥ 4 weeks from other investigational anticancer therapy

          -  Agree to practice effective contraception

        Exclusion Criteria:

          -  Known CNS involvement by leukemia

          -  Currently receiving radiotherapy, biological therapy, or any other investigational
             agents

          -  Uncontrolled intercurrent illness

          -  Pregnant or lactating

          -  Known to be HIV-positive

          -  Known active hepatitis B and/ or hepatitis C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautam Borthakur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy Chiao, MD</last_name>
    <phone>908.517.7330</phone>
    <email>jchiao@cyclacel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hind Alazzawi</last_name>
      <phone>713-794-4823</phone>
      <email>halazzawi@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML, ALL, CLL, CML, MDS, advanced leukemias, leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

